Agenda

A focus on bladder, kidney and prostate cancers.

The 2026 World Conference on Genitourinary Cancers brings together multidisciplinary experts to explore innovation, evidence, and practical strategies that elevate care across prostate, bladder, and kidney cancers. The program moves in a logical progression from emerging technologies to real‑world clinical application, offering a focused and collaborative learning experience.

2026 aGENDA

Explores how rapidly advancing technologies—especially artificial intelligence—are influencing imaging, pathology, and clinical decision‑making, with attention to both opportunities and limitations.
Reviews evolving systemic treatment modalities, comparing mechanisms, applications, and selection factors for modern therapeutic approaches used across GU cancers.
Highlights multidisciplinary management of high‑risk disease, demonstrating how coordinated workflows between specialties influence outcomes and patient experience.
Provides practical guidance on adapting evidence to daily practice, including dose adjustments, treatment holds, consolidative strategies, and evolving supportive care.
Addresses rare and less common GU histologies, outlining diagnostic and therapeutic challenges and how clinicians navigate limited evidence using multidisciplinary insights.
Examines emerging tools and capabilities shaping the next era of oncology practice, including advances in genomic testing, molecular diagnostics, imaging, digital health, and focal therapy strategies.
Discusses subtle but clinically meaningful factors in detection and recurrence monitoring, including biomarkers, imaging refinements, and considerations for high‑risk screening populations.
Explores how clinicians balance treatment intensity—escalation vs. de‑escalation—based on disease biology, patient characteristics, and evolving evidence across tumor types.
Outlines real‑world integration of combination approaches and therapeutic partners, offering practical insights for community and academic settings.
Summarizes the evolving treatment landscape with concise updates on new data, shifting standards, and upcoming developments for major GU cancers.
Synthesizes program themes through applied, case‑driven discussions that demonstrate multidisciplinary coordination and practical decision‑making across complex scenarios.
Concludes with an engaging educational finale designed to reinforce learning and celebrate collaborative progress within the GU oncology community.

The 2026 program delivers a comprehensive, forward‑looking experience that bridges scientific advancement with real‑world practice, emphasizing the value of multidisciplinary care and equipping clinicians with actionable insights to improve outcomes across the genitourinary cancer spectrum.

Thursday, December 3, 2026

Welcome Day

Poster Session & Welcome Reception

friday, December 4, 2026

day one

The Role of AI in GU Cancers

King Kong vs Godzilla: ADC vs RLT

Multidisciplinary Care of High-Risk Patients in GU Cancers

Rubber Meets the Road for Real-World Management in GU Cancers – Part I

How I Manage Rare Histologies

Tools for Tomorrow’s Oncologist

Saturday, December 5, 2026

day two

The Big Deal about Small Things in GU Cancers

Strategy and Balance: Finding the Optimal Intensity

Rubber Meets the Road for Real-World Management in GU Cancers – Part 2

The Evolving Landscape

Application Panel

Final World GU-Pardy!

Thursday | August 21

Poster Session & Welcome Reception

Friday | August 22

Breakfast

MDT Advancements in Staging and Treatment Planning in GU Cancers

CHAIR: Ashley Ross, MD, PhD (Northwestern Medicine)

Theranostics in Prostate: Critical Role of Imaging

Heather Jacene, MD (Brigham and Women's Hospital) & Kerry Schaffer, MD (Vanderbilt University Medical Center)

Panel Discussion

How Do You Define Locally Advanced Bladder Cancer?

Michael Woods, MD (Loyola University) & Matthew Milowsky, MD (University of North Carolina)

Panel Discussion

Diagnosis and Management of Indeterminant Metastasis in Kidney Cancer

Brian Shuch, MD (University of California Los Angeles) & Rajan Gupta, MD (Duke Cancer Center)

Panel Discussion and Q&A

Networking Break

Managing Early-Stage Disease

CHAIR: Stacy Loeb, MD (NYU Langone Health & Manhattan VA)

Early-Stage Kidney: Surgery, Ablation and Active Surveillance

Phillip Pierorazio, MD (University of Pennsylvania)

Early-Stage Bladder: The Evolving Landscape

Sam Chang, MD, MBA (Vanderbilt University Medical Center)

Early-Stage Prostate: Novel Diagnostics, Focal Therapy and Active Surveillance

Daniel Barocas, MD (Vanderbilt University Medical Center)

Radiation Chip Shots: Small Tumors and Localized Disease

Eric Shinohara, MD (Vanderbilt University Medical Center)

Panel Discussion and Q&A

Mark Fleming, MD (Virginia Oncology Associates)

Lunch Symposium (Non-CE)

Multidisciplinary Care of High-Risk Patients in GU Cancers

CHAIR: Karen Hoffman, MD, MHSc, MPH, FASTRO

High-Risk Kidney Cancer

Naomi Haas, MD (University of Pennsylvania) & Michael Abern, MD (Duke Cancer Center)

Panel Discussion

High-Risk Prostate Cancer

James Eastham, MD (Memorial Sloan Kettering Cancer Center) & Jonathan Leeman, MD (Harvard Medical School)

Panel Discussion and Q&A

High-Risk Bladder Cancer

Jason Efstathiou, MD, DPHIL (Massachusetts General Hospital) & Monika Joshi, MD (Penn State Cancer Institute)

Panel Discussion and Q&A

Networking Break

Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part I: Maximizing MDT Resources

CHAIR: Mehmet Bilen, MD (Winship Cancer Institute of Emory University)

Case-Based Approach to Oligometastatic Renal Disease

Michael Harrison, MD (Duke Cancer Center)

Case-Based Approach to Locally Advanced Bladder Cancer

Kristin Scarpato, MD (Vanderbilt University Medical Center)

The Current State of mHSPC: Volume of Disease and Treatment Management

Elizabeth Kessler, MD (University of Colorado Health)

Risk Stratification and Future Developments in Precison Management of Prostate Cancer

Mutlay Sayan, MD (Harvard Medical School)

Panel Discussion and Q&A

John Phillips, MD (Tennessee Oncology)

Classifying and Managing Rare Histologies Across GU Cancers

CHAIR: Manojkumar Bupathi, MD, MS (Rocky Mountain Cancer Center)

Classifying Rare Histologies

Jiaoti Huang, MD, PhD (Duke Cancer Center)

How do you Manage Rare Bladder Histologies?

Arlene Siefker-Radtke, MD (MD Anderson Cancer Center)

Managing Upper Tract Urothelial Carcinoma

Jeannie Hoffman-Censits, MD (Johns Hopkins Kimmel Cancer Center)

Management of Rare Kidney Histologies

Darren Feldman, MD (Memorial Sloan Kettering Cancer Center)

Panel Discussion and Q&A

Bradley Somer, MD (West Cancer Center & Research Institute)

Keynote Presentation (Non-CE)

Chaunté Lowe

4x Olympian
Founder & CEO
Boundless Resilience

Saturday | August 23

Breakfast

Tools for Tomorrow's Oncologist

CHAIR: Katy Beckermann, MD, PhD (Tennessee Oncology)

Role of Precision Medicine

Ulka Vaishampayan, MD (University of Michigan)

Trials in Progress in Early-Stage Therapeutics

Elisabeth Heath, MD (Mayo Clinic)

Patient Frailty/FIT Levels

Stephanie Berg, DO (Harvard Medical School)

Palliative Care & Decision Making

Elizabeth Wulff-Burchfield, MD (University of Kansas)

Implementing Pathways in an Evolving Landscape

Lisa Raff, PharmD (OneOncology)

Improving Communication in a Multidisciplinary Environment

Kelvin Moses, MD, PhD (Vanderbilt University Medical Center)

Q&A

Networking Break

Strategies for the Implementation of MRD in GU Cancers

CHAIR: Benjamin Maughan, MD (Huntsman Cancer Institute)

Defining MRD

Alan Tan, MD (Vanderbilt University Medical Center)

Using ctDNA to measure MRD in Bladder Cancer

Elizabeth Plimack, MD (Fox Chase Cancer Center)

What's Different with MRD in Prostate?

Michael Schweizer, MD (Fred Hutch Cancer Center)

Controversies in Imaging MRD: PSMA PET and Biochemical Recurrence

Ravi Madan, MD (National Institutes of Health)

How Can We Better Measure MRD in Kidney?

Brian Rini, MD (Vanderbilt University Medical Center)

Panel Discussion and Q&A

Jeffrey Yorio, MD (Texas Oncology)

Special Session

Introduction

Daniel George, MD (Duke Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Fireside Chat with Robert Califf, MD, MACC, former FDA Commissioner

Robert Califf, MD, MACC (Duke University Medical Center)

Lunch Symposium (Non-CE)

Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part 2

CHAIR: Edwin Posadas, MD (Cedars Sinai Medical Center)

Case-Based Approach to PARP Inhibitors in Prostate Cancer

Chandler Park, MD (Norton Healthcare)

Case-Based Approach to Kidney Cancer

Hans Hammers, MD, PhD (UT Southwestern Medical Center)

Bladder MIBC Systemic Therapy and Outcomes

Jacqueline Brown, MD (Winship Cancer Institute of Emory University)

Panel Discussion and Q&A

Michael Lattanzi, MD (Texas Oncology)

Early-Stage Therapeutics: New Drugs in the Contemporary Landscape

CHAIR: Robert Dreicer, MD (University of Virginia)

Emerging Approaches to Bladder Cancer

Karine Tawagi, MD (University of Illinois at Chicago)

Emerging Approaches to Prostate Cancer

Benjamin Garmezy, MD (Sarah Cannon Research Institute)

Emerging Approaches to Kidney Cancer

Eric Jonasch, MD (MD Anderson Cancer Center)

Harnessing Resistance to Immunotherapy Approaches in Kidney Cancer

David Braun, MD, PhD (Yale Medicine)

Q&A

Networking Break

Applying the Good News into Everyday Practice

CHAIRS: Charles Ryan, MD (Memorial Sloan Kettering Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Monday Morning Quick Start

World GU-Pardy

HOST: Mark Pomerantz, MD (Harvard Medical School)

Farewell Reception

Experience Nashville, TN

Come for the education. Stay for the fun.